FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
May 29, 2025
Foley Viewpoints
Keep Wining: Franchise Statute Opens Door to Protections for Missouri Wine Distributor
The Eighth Circuit recently applied a novel, broad reading of the Missouri Franchise Act granting franchise protection to distributors…
May 28, 2025
Foley Viewpoints
U.S. and International Antitrust Agencies Signal Aggressive Antitrust Enforcement in Procurement, Consumer Products, and Labor Markets
As we previously reported on April 15 and April 28, the Department of Justice (DOJ) and Federal Trade Commission (FTC) are increasingly…
May 28, 2025
Foley Viewpoints
Rethinking University Research: Innovating the Innovation Ecosystem to Support Life Sciences and Personalized Medicine
Personalized medicine—tailoring treatments to individual patients based on their genetic makeup, lifestyle, and environment—is…